226 related articles for article (PubMed ID: 23466567)
21. Cancer Fighting SiRNA-RRM2 Loaded Nanorobots.
Sharma A; Kumar P; Ambasta RK
Pharm Nanotechnol; 2020; 8(2):79-90. PubMed ID: 32003677
[TBL] [Abstract][Full Text] [Related]
22. [Vector construction and silencing effect of Edg4 gene targeted small interfering RNA in ovarian cancer cell line].
Qiao YH; Li LX; Guo RX; Zhou W; Wang M; Zhang XY; Zhang JH; Zhao XL; Zhang MZ; Zhao GQ
Zhonghua Fu Chan Ke Za Zhi; 2007 Nov; 42(11):765-9. PubMed ID: 18307905
[TBL] [Abstract][Full Text] [Related]
23. Noscapine Increases the Sensitivity of Drug-Resistant Ovarian Cancer Cell Line SKOV3/DDP to Cisplatin by Regulating Cell Cycle and Activating Apoptotic Pathways.
Shen W; Liang B; Yin J; Li X; Cheng J
Cell Biochem Biophys; 2015 May; 72(1):203-13. PubMed ID: 25510462
[TBL] [Abstract][Full Text] [Related]
24. Gambogic acid sensitizes gemcitabine efficacy in pancreatic cancer by reducing the expression of ribonucleotide reductase subunit-M2 (RRM2).
Xia G; Wang H; Song Z; Meng Q; Huang X; Huang X
J Exp Clin Cancer Res; 2017 Aug; 36(1):107. PubMed ID: 28797284
[TBL] [Abstract][Full Text] [Related]
25. Inhibiting RRM2 to enhance the anticancer activity of chemotherapy.
Zhan Y; Jiang L; Jin X; Ying S; Wu Z; Wang L; Yu W; Tong J; Zhang L; Lou Y; Qiu Y
Biomed Pharmacother; 2021 Jan; 133():110996. PubMed ID: 33227712
[TBL] [Abstract][Full Text] [Related]
26. Ribonucleotide reductase small subunit M2 is a master driver of aggressive prostate cancer.
Mazzu YZ; Armenia J; Nandakumar S; Chakraborty G; Yoshikawa Y; Jehane LE; Lee GM; Atiq M; Khan N; Schultz N; Kantoff PW
Mol Oncol; 2020 Aug; 14(8):1881-1897. PubMed ID: 32385899
[TBL] [Abstract][Full Text] [Related]
27. Emerging roles of the ribonucleotide reductase M2 in colorectal cancer and ultraviolet-induced DNA damage repair.
Lu AG; Feng H; Wang PX; Han DP; Chen XH; Zheng MH
World J Gastroenterol; 2012 Sep; 18(34):4704-13. PubMed ID: 23002339
[TBL] [Abstract][Full Text] [Related]
28. Implication of checkpoint kinase-dependent up-regulation of ribonucleotide reductase R2 in DNA damage response.
Zhang YW; Jones TL; Martin SE; Caplen NJ; Pommier Y
J Biol Chem; 2009 Jul; 284(27):18085-95. PubMed ID: 19416980
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of microRNA-196a might reverse cisplatin resistance of A549/DDP non-small-cell lung cancer cell line.
Li JH; Luo N; Zhong MZ; Xiao ZQ; Wang JX; Yao XY; Peng Y; Cao J
Tumour Biol; 2016 Feb; 37(2):2387-94. PubMed ID: 26376998
[TBL] [Abstract][Full Text] [Related]
30. Gemcitabine-based chemogene therapy for pancreatic cancer using Ad-dCK::UMK GDEPT and TS/RR siRNA strategies.
Réjiba S; Bigand C; Parmentier C; Hajri A
Neoplasia; 2009 Jul; 11(7):637-50. PubMed ID: 19568409
[TBL] [Abstract][Full Text] [Related]
31. [Suppression of ATR reverses the cisplatin resistance in ovarian cancer SKOV3 cells].
Yang Z; Sun C; Liu Y; Gong C; Chen G; Weng D
Zhonghua Zhong Liu Za Zhi; 2014 Nov; 36(11):805-10. PubMed ID: 25620475
[TBL] [Abstract][Full Text] [Related]
32. [Effect of S1PR2 inhibition on epithelial ovarian cancer SKOV3 cell proliferation in vitro and in vivo].
Dai L; Liu YX; Xie L; Di W
Zhonghua Fu Chan Ke Za Zhi; 2018 Feb; 53(2):106-110. PubMed ID: 29534379
[No Abstract] [Full Text] [Related]
33. [Study on RNA interference silencing hMSH2 induces the reversal chemo-resistance of ovarian carcinoma cell line OC3/TAX300].
Wang A; Li J; Li H
Zhonghua Fu Chan Ke Za Zhi; 2014 Mar; 49(3):213-7. PubMed ID: 24820308
[TBL] [Abstract][Full Text] [Related]
34. [Specific inhibition of HER-2 expression in ovarian carcinoma cells by siRNA targeting HER-2].
Lu YM; Zhang SL; Meng LR; Zhao YY
Zhonghua Yi Xue Za Zhi; 2006 Mar; 86(9):619-23. PubMed ID: 16681908
[TBL] [Abstract][Full Text] [Related]
35. Effect of cyclin-dependent kinase 7 silencing on cisplatin sensitivity in endometrial carcinoma cells.
Liu WX; Liu XY; Yu H; Chen Y; Hao Q
Mol Med Rep; 2015 Mar; 11(3):1745-51. PubMed ID: 25411854
[TBL] [Abstract][Full Text] [Related]
36. ERCC1 siRNA ameliorates drug resistance to cisplatin in gastric carcinoma cell lines.
Li W; Jie Z; Li Z; Liu Y; Gan Q; Mao Y; Wang X
Mol Med Rep; 2014 Jun; 9(6):2423-8. PubMed ID: 24699918
[TBL] [Abstract][Full Text] [Related]
37. The promoted delivery of RRM2 siRNA to vascular smooth muscle cells through liposome-polycation-DNA complex conjugated with cell penetrating peptides.
Wu Y; Sun J; Li A; Chen D
Biomed Pharmacother; 2018 Jul; 103():982-988. PubMed ID: 29710515
[TBL] [Abstract][Full Text] [Related]
38. Identification of ribonucleotide reductase M2 as a potential target for pro-senescence therapy in epithelial ovarian cancer.
Aird KM; Li H; Xin F; Konstantinopoulos PA; Zhang R
Cell Cycle; 2014; 13(2):199-207. PubMed ID: 24200970
[TBL] [Abstract][Full Text] [Related]
39. [Effect of RBP2 gene silencing on proliferation, migration and invasion of ovarian epithelial cancer SKOV3/DDP cells and its mechanism].
Feng TF; Yao DM; Zheng R; Jiang DS; Zhang LL; Xing Q; Li L
Zhonghua Zhong Liu Za Zhi; 2022 Feb; 44(2):139-146. PubMed ID: 35184457
[No Abstract] [Full Text] [Related]
40. Small molecule inhibitor of c-Met (PHA665752) suppresses the growth of ovarian cancer cells and reverses cisplatin resistance.
Li E; Hu Z; Sun Y; Zhou Q; Yang B; Zhang Z; Cao W
Tumour Biol; 2016 Jun; 37(6):7843-52. PubMed ID: 26695152
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]